LYDISILKA

This brand name is authorized in Austria, Estonia, Croatia, Ireland, Lithuania, Poland

Active ingredients

The drug LYDISILKA contains a combination of these active pharmaceutical ingredients (APIs):

1 Drospirenone UNII N295J34A25 - DROSPIRENONE

Drospirenone is a progestogen. In a therapeutic dosage, drospirenone also possesses antiandrogenic and mild antimineralocorticoid properties. It has no estrogenic, glucocorticoid and antiglucocorticoid activity. This gives drospirenone a pharmacological profile closely resembling the natural hormone progesterone. Read about Drospirenone

2 Estetrol UNII ENB39R14VF - ESTETROL ANHYDROUS

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
G03AA18		G Genito urinary system and sex hormones → G03 Sex hormones and modulators of the genital system → G03A Hormonal contraceptives for systemic use → G03AA Progestogens and estrogens, fixed combinations
Discover more medicines within G03AA18

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1849428, 1849439, 1849440, 1849451
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1092681, 1092683, 1092684, 1092685
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100455180